This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Series

Agamemnon Epenetos, PhD, FRCP
Consultant in Clinical Oncology at The Harley Street Clinic
Speaker

Profile

Agamemnon Epenetos qualified in medicine from Glasgow University, Scotland in 1973 and subsequently specialized in Medical Oncology at St. Bartholomew's Hospital, London where he held an Honorary Consultant appointment in Medical Oncology.

He has been a practicing Oncologist and Cancer Researcher over the last 30 years. He was, until recently, a visiting Professor at Imperial College London. He has published widely on novel cancer therapies and has received much international recognition.

Agamemnon has more than 20 years of experience as a biopharmaceutical industry executive. He founded (1988) and served (1990- 2001) as Chairman and R&D Director of Antisoma plc, an oncology-focused biotechnology company listed on the London Stock Exchange and now trading as Sarossa plc (sarossaplc.com). He co-founded (2001) and served as Chairman (2001-2004) of Lipoxen plc, a drug delivery and vaccine company listed on the AIM Market ( and now trading on NASDAQ as Xenetic Biosciences (www.xeneticbio.com). He also founded (2004) and served as President and CEO (2004-2007) of Somanta Inc. a US cancer therapeutics company listed on the USA OTC/BB. Somanta was acquired in 2007 by Access Pharma Inc., a cancer therapeutics company now trading on NASDAQ as Abeona Therapeutics (www.abeonatherapeutics.com). He co-founded Trojantec Ltd and Alexis Biotech Ltd cancer therapeutic companies, which unfortunately ceased business.

He founded and is chairing a private company Lifeline (www.lifeline.com.cy) a stem cell storage company developing regenerative medicine cell products.